PLRX – pliant therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
Pliant Therapeutics (NASDAQ:PLRX) was upgraded by analysts at Wall Stree
Pliant Therapeutics (NASDAQ:PLRX) had its price target lowered by analysts at Royal Bank Of Canada from $3.00 to $2.00. They now have a "sector perform" rating on the stock.
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Form SCHEDULE 13G PLIANT THERAPEUTICS, Filed by: Woodline Partners LP
Form SCHEDULE 13G/A PLIANT THERAPEUTICS, Filed by: Deep Track Capital, LP
Form 10-Q PLIANT THERAPEUTICS, For: Sep 30
Form 8-K PLIANT THERAPEUTICS, For: Nov 06
Form 8-K PLIANT THERAPEUTICS, For: Oct 20
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.